European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“The ESMO 2026 Congress will be a place to transform the way you treat cancer, to discover innovations, collaborate with experts and advance your practice with real-world insights from international experts.
Look at what our Genitourinary tumours, prostate, penile and testis Track Chair, Christopher Sweeney, is looking forward to at this year’s event.
Register by 22 July 2026 to benefit from the most advantageous fees.
Learning objectives:
- To stay informed about current approaches in cancer prevention, screening, and early detection
- To gain insights into the latest advances in basic, translational, and clinical cancer research
- To explore the clinical implications of scientific breakthroughs in cancer biology, diagnostics, and treatment
- To be updated on state-of-the-art therapeutic strategies for patients with cancer
- To examine the emerging role of artificial intelligence in cancer diagnosis, research and therapy”
Professor Christopher Sweeney is a globally recognized leader in genitourinary oncology and the inaugural Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI). With an illustrious career that includes a decade-long tenure as a Professor at Harvard Medical School and a Senior Physician at Dana-Farber Cancer Institute, he has pioneered practice-changing research in prostate and testicular cancers.
As a clinician-researcher, Professor Sweeney is renowned for leading landmark clinical trials such as the CHAARTED and ENZAMET studies, which have fundamentally redefined the standard of care for men with metastatic prostate cancer worldwide.
Other articles about Genitourinary Cancer on OncoDaily.